Latham & Watkins has advised Eleusis, a life science company dedicated to unlocking the full therapeutic potential of psychedelics, on the sale of the company to Beckley Psytech, a leading clinical-stage company developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines. The consideration for the transaction comprises entirely of shares in Beckley Psytech.
Latham previously advised Eleusis on its de-SPAC transaction with Silver Spike.
The Latham team was led by London corporate partner Robbie McLaren and Bay Area partner Haim Zaltzman, with London associates Jon Fox, Samantha Si, Alayna Kenney, and Saavan Shah.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
